Evidence map›Paper›PMID 42148780›Full record

ArticleProtein science : a publication of the Protein Society2026

Joint modeling of longitudinal and time-to-event data for dynamic disease risk prediction using proteomics.

Markus Lindén, Tea Ammunét, Tommi Välikangas, Laura L Elo, Tomi Suomi

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Markus LindénTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID 0000-0001-7108-9653
Tea AmmunétTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Tommi VälikangasTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Laura L EloTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID 0000-0001-5648-4532
Tomi SuomiTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID 0000-0003-3639-979X

Funding

Academy of Finland 310561Academy of Finland 314443Academy of Finland 329278Academy of Finland 335434Academy of Finland 335611Academy of Finland 341342Biocenter FinlandELIXIR FinlandEuropean Research Council 677943H2020 European Research Council 955321Sigrid Juséliuksen SäätiöVilho, Yrjö and Kalle Väisälä Foundation
6 · The paper itself

Abstract

Biomedical studies increasingly incorporate longitudinal data, enabling us to track individual disease processes over time at the molecular level, and to discover associations of the molecular profiles with the outcome of interest, such as the onset of a disease. Despite the potential of statistical methods that jointly model longitudinal and time-to-event data, they have not yet been widely adopted in high-throughput omics studies. Therefore, we evaluated multiple approaches for joint modeling of longitudinal and time-to-event data, and we introduce a joint modeling strategy for longitudinal proteomics studies. The focus is on assessing the utility of the methods in predicting the dynamic disease risk of an individual from longitudinal proteome profiles. To benchmark the methods, we used a range of simulated datasets that reflected real proteome profiles with varying complexities. Our results clearly demonstrated the advantages of the longitudinal methods over conventional Cox proportional hazards models with single time point studies. This was further supported by re-analysis of data from a proteomics study of early type 1 diabetes prediction, where we discovered new early candidate proteins associated with the disease onset that were not detected in the original study.

Indexed as

Diabetes Mellitus, Type 1ProteomeProteomicsHumansLongitudinal StudiesProportional Hazards ModelsProteomejoint modellongitudinalrisk predictionsurvival analysistype 1 diabetes

Identifiers

PMID42148780
PMCPMC13182269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.